These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 1944210)
21. Clinical results of treatment of postsurgical endotoxin-mediated sepsis with polymyxin-B direct hemoperfusion. Novelli G; Ferretti G; Poli L; Pretagostini R; Ruberto F; Perrella SM; Levi Sandri GB; Morabito V; Berloco PB Transplant Proc; 2010 May; 42(4):1021-4. PubMed ID: 20534214 [TBL] [Abstract][Full Text] [Related]
22. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat. Toth PD; Mikulaschek AW Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423 [TBL] [Abstract][Full Text] [Related]
23. Immunoprophylaxis and immunotherapy of Gram-negative infections in the immunocompromised host. Glauser MP; McCutchan JA; Ziegler E Clin Haematol; 1984 Oct; 13(3):549-55. PubMed ID: 6388931 [TBL] [Abstract][Full Text] [Related]
24. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121 [TBL] [Abstract][Full Text] [Related]
27. Platelet and plasma platelet-activating factor in sepsis and myocardial infarction. Graham RM; Strahan ME; Norman KW; Watkins DN; Sturm MJ; Taylor RR J Lipid Mediat Cell Signal; 1994 Mar; 9(2):167-82. PubMed ID: 8012763 [TBL] [Abstract][Full Text] [Related]
28. Early outcome after surgery for active native and prosthetic aortic valve endocarditis. Gabbieri D; Dohmen PM; Linneweber J; Grubitzsch H; von Heymann C; Neumann K; Halle E; Konertz WF J Heart Valve Dis; 2008 Sep; 17(5):508-24; discussion 525. PubMed ID: 18980085 [TBL] [Abstract][Full Text] [Related]
29. [Management of tertiary peritonitis in the patients complicated with intestinal fistula]. Ren JA; Wang GF; Fan CG; Wang XB; Jiang J; Wang ZM; Gu J; Li JS Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jul; 9(4):284-6. PubMed ID: 16886103 [TBL] [Abstract][Full Text] [Related]
34. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ]. Baudo F; de Cataldo F Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542 [TBL] [Abstract][Full Text] [Related]
35. Clinical and experimental studies on the role of platelet-activating factor (PAF) in the pathogenesis of septic DIC. Ono S; Tamakuma S; Mochizuki H; Kinoshita M; Ohkusa Y; Aosasa S; Oda Y; Ohe H Surg Today; 1993; 23(3):228-33. PubMed ID: 8467174 [TBL] [Abstract][Full Text] [Related]
36. [Clinico-experimental analysis of backgrounds of the severe surgical infections]. Ono S; Tamakuma S; Mochizuki H; Kadota T; Yamamoto T Nihon Geka Gakkai Zasshi; 1991 Sep; 92(9):1300-3. PubMed ID: 1944210 [TBL] [Abstract][Full Text] [Related]
38. A clinical study on the significance of platelet-activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery. Ono S; Mochizuki H; Tamakuma S Am J Surg; 1996 Apr; 171(4):409-15. PubMed ID: 8604832 [TBL] [Abstract][Full Text] [Related]
39. [Clinical and experimental studies of septic DIC in surgical patients, in terms of its characteristic features and pathogenesis]. Ono S Nihon Geka Gakkai Zasshi; 1994 Dec; 95(12):849-59. PubMed ID: 7877583 [TBL] [Abstract][Full Text] [Related]
40. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]